Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

NCT04758897 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumor

Interventions

DRUG: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Sponsor

CNBG-Virogin Biotech (Shanghai) Ltd.